XERS

Xeris Biopharma Holdings

• Simply Wall St·1d ago

  A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Q4 2025 Earnings Beat

• Reuters·4d ago

  Xeris Biopharma Chief Legal Officer Beth Hecht sells under $1 million common shares

• Reuters·4d ago

  Xeris grants 305,000 restricted stock units to 90 new employees under inducement plan

• Reuters·4d ago

  XERIS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

• Reuters·6d ago

  Xeris Biopharma director James Brady disposes of USD 0.1 million common shares

• Reuters·03/23 11:31

  Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services

• TipRanks·03/19 08:40

  Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), CytomX Therapeutics (CTMX) and Johnson & Johnson (JNJ)

• Simply Wall St·03/09 03:17

  Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance

• TipRanks·03/09 00:21

  Xeris Pharmaceuticals Earnings Call Highlights Rapid Growth

• Reuters·03/04 22:29

  Xeris Biopharma Chief Legal Officer and Corporate Secretary Beth Hecht Disposes of Common Shares

• Seeking Alpha·03/04 12:29

  Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio

• TipRanks·03/03 15:50

  Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Xeris Pharmaceuticals (XERS)

• Simply Wall St·03/03 00:37

  Xeris Biopharma (XERS) Turns Trailing Profitability Into Test Of Bullish Growth Narrative

• Dow Jones·03/02 17:44

  Xeris Biopharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

• Benzinga·03/02 17:34

  HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target